- Home
- ALX vs COLL Comparison
ALX vs COLL Comparison
Compare ALX & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALX | COLL |
|---|---|---|
| Founded | 1928 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ALX | COLL |
|---|---|---|
| Price | $265.03 | $27.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $51.40 |
| AVG Volume (30 Days) | 19.2K | ★ 672.1K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 31.15 | N/A |
| Revenue | $213,183,000.00 | ★ $780,567,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.74 | ★ N/A |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $201.28 | $25.47 |
| 52 Week High | $289.43 | $50.79 |
Technical Indicators
Market Signals| Indicator | ALX | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 32.07 |
| Support Level | $252.20 | $25.47 |
| Resistance Level | $271.02 | $36.25 |
| Average True Range (ATR) | 6.66 | 1.50 |
| MACD | -0.42 | -0.21 |
| Stochastic Oscillator | 29.45 | 14.79 |
Price Performance
Historical ComparisonAbout ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.